MPG.eBooks - Description: CADTH Canadian Drug Expert Committee recommendation: Ofatumumab (Kesimpta -- Novartis Hharmaceuticals Canada Inc.)

Cover Image

Read Now

CADTH Canadian Drug Expert Committee recommendation: Ofatumumab (Kesimpta -- Novartis Hharmaceuticals Canada Inc.) indication : multiple sclerosis, relapsing-remitting

Ofatumumab has a Health Canada indication for the treatment of adult patients with RRMS with active disease defined by clinical and imaging features. Ofatumumab is a human monoclonal antibody

Bibliographic Details
Corporate Authors:	CADTH Canadian Drug Expert Committee, Canadian Agency for Drugs and Technologies in Health
Format:	eBook
Language:	English
Published:	Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2021, March 2021
Edition:	Version: 1.0
Series:	CADTH common drug review
Online Access:	https://www.ncbi.nlm.nih.gov/books/NBK572299
Collection:	National Center for Biotechnology Information - Collection details see MPG.ReNa

Description
Summary:	Ofatumumab has a Health Canada indication for the treatment of adult patients with RRMS with active disease defined by clinical and imaging features. Ofatumumab is a human monoclonal antibody
Item Description:	"Final."
Physical Description:	1 PDF file (9 pages)